Adverse effects associated with tirzepatide: Focus on musculoskeletal symptoms
The skeptical cardiologist, like most physicians, has always assumed that weight loss, whether accomplished by diet/exercise, bariatric surgery, or drugs would benefit obese patients since it lowers blood pressure, cholesterol and blood sugar levels
Constipation was reported in 24.2% of people taking semaglutide, compared to 11.1% taking the placebo
Since further research is necessary to determine if semaglutide directly causes NAION, it is advised that people who have not experienced any symptoms should continue to take their medications as prescribed
Since these medications mimic this natural hormone, they can: Reduce appetite and help manage blood sugar Help the pancreas release the right amount of insulin Slow how quickly food leaves the stomach, which helps you feel full longer Many GLP1 agonists are taken as injections
What payers require for Mounjaro prior authorization For Mounjaro (diabetes indication), most payers require: Confirmed type 2 diabetes diagnosis with recent HbA1c level (typically above 7.0%) Documentation of current diabetes medications and their inadequacy (most plans require failure of metformin unless contraindicated) Step therapy documentation showing the patient has tried first-line agents before progressing to tirzepatide Prescriber specialty (some plans restrict initial prescribing to endocrinologists or require specialist consultation) The PA request uses the tirzepatide dosing schedule as part of the clinical rationale
